The objective of this communication is to report our recent experience with this agent during cardiopulmonary bypass (CPB) and to review the cases previously published in order to better define indications, dosage, monitoring and limitations in cardiac surgery patients.
In this review, we discuss the use of various modes of kidney replacement therapy in treating renal and non‐renal complications to illustrate why kidney support therapy is a more appropriate terminology than renal replacement therapy.